|
1
|
Modrek AS, Bayin NS and Placantonakis DG:
Brain stem cells as the cell of origin in glioma. World J Stem
Cells. 6:43–52. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Lapointe S, Perry A and Butowski NA:
Primary brain tumours in adults. Lancet. 392:432–446. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Wesseling P and Capper D: WHO 2016
Classification of gliomas. Neuropathol Appl Neurobiol. 44:139–150.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Alifieris C and Trafalis DT: Glioblastoma
multiforme: Pathogenesis and treatment. Pharmacol Ther. 152:63–82.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Sun Q, Xu R, Xu H, Wang G, Shen X and
Jiang H: Extracranial metastases of high-grade glioma: The clinical
characteristics and mechanism. World J Surg Oncol. 15:1812017.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Chang JC: Cancer stem cells: Role in tumor
growth, recurrence, metastasis, and treatment resistance. Medicine
(Baltimore). 95 (Suppl 1):S20–S25. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Auffinger B, Tobias AL, Han Y, Lee G, Guo
D, Dey M, Lesniak MS and Ahmed AU: Conversion of differentiated
cancer cells into cancer stem-like cells in a glioblastoma model
after primary chemotherapy. Cell Death Differ. 21:1119–1131. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Bhan A, Soleimani M and Mandal SS: Long
noncoding RNA and cancer: A new paradigm. Cancer Res. 77:3965–3981.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Ignarski M, Islam R and Müller RU: Long
non-coding RNAs in kidney disease. Int J Mol Sci. 20:32762019.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Huang Y: The novel regulatory role of
lncRNA-miRNA-mRNA axis in cardiovascular diseases. J Cell Mol Med.
22:5768–5775. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Buccarelli M, Lulli V, Giuliani A, Signore
M, Martini M, D'Alessandris QG, Giannetti S, Novelli A, Ilari R,
Giurato G, et al: Deregulated expression of the imprinted DLK1-DIO3
region in glioblastoma stemlike cells: Tumor suppressor role of
lncRNA MEG3. Neuro Oncol. 22:1771–1784. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Lu C, Wei Y, Wang X, Zhang Z, Yin J, Li W,
Chen L, Lyu X, Shi Z, Yan W and You Y: DNA-methylation-mediated
activating of lncRNA SNHG12 promotes temozolomide resistance in
glioblastoma. Mol Cancer. 19:282020. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Voce DJ, Bernal GM, Wu L, Crawley CD,
Zhang W, Mansour NM, Cahill KE, Szymura SJ, Uppal A, Raleigh DR, et
al: Temozolomide treatment induces lncRNA MALAT1 in an NF-κB and
p53 codependent manner in glioblastoma. Cancer Res. 79:2536–2548.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Li J, Zhang M, An G and Ma Q: LncRNA TUG1
acts as a tumor suppressor in human glioma by promoting cell
apoptosis. Exp Biol Med (Maywood). 241:644–649. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zhao Z, Wang B, Hao J, Man W, Chang Y, Ma
S, Hu Y, Liu F and Yang J: Downregulation of the long non-coding
RNA taurine-upregulated gene 1 inhibits glioma cell proliferation
and invasion and promotes apoptosis. Oncol Lett. 15:4026–4032.
2018.PubMed/NCBI
|
|
16
|
Margueron R and Reinberg D: The Polycomb
complex PRC2 and its mark in life. Nature. 469:343–349. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wang XP, Shan C, Deng XL, Li LY and Ma W:
Long non-coding RNA PAR5 inhibits the proliferation and progression
of glioma through interaction with EZH2. Oncol Rep. 38:3177–3186.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Krell A, Wolter M, Stojcheva N, Hertler C,
Liesenberg F, Zapatka M, Weller M, Malzkorn B and Reifenberger G:
MiR-16-5p is frequently down-regulated in astrocytic gliomas and
modulates glioma cell proliferation, apoptosis and response to
cytotoxic therapy. Neuropathol Appl Neurobiol. 45:441–458.
2019.PubMed/NCBI
|
|
19
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
National Research C: Guide for the Care
and Use of Laboratory Animals. 8th edition. The National Academies
Press; Washington, DC: 2011
|
|
21
|
Chumakova A and Lathia JD: Outlining
involvement of stem cell program in regulation of O6-methylguanine
DNA methyltransferase and development of temozolomide resistance in
glioblastoma: An Editorial Highlight for ‘Transcriptional control
of O6 -methylguanine DNA methyltransferase expression
and temozolomide resistance in glioblastoma’ on page 780. J
Neurochem. 144:688–690. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Safa AR, Saadatzadeh MR, Cohen-Gadol AA,
Pollok KE and Bijangi-Vishehsaraei K: Glioblastoma stem cells
(GSCs) epigenetic plasticity and interconversion between
differentiated non-GSCs and GSCs. Genes Dis. 2:152–163. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Lee SY: Temozolomide resistance in
glioblastoma multiforme. Genes Dis. 3:198–210. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Stupp R, Mason WP, van den Bent MJ, Weller
M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn
U, et al: Radiotherapy plus concomitant and adjuvant temozolomide
for glioblastoma. N Engl J Med. 352:987–996. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Thakkar JP, Dolecek TA, Horbinski C,
Ostrom QT, Lightner DD, Barnholtz-Sloan JS and Villano JL:
Epidemiologic and molecular prognostic review of glioblastoma.
Cancer Epidemiol Biomarkers Prev. 23:1985–1996. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Ostrom QT, Gittleman H, Xu J, Kromer C,
Wolinsky Y, Kruchko C and Barnholtz-Sloan JS: CBTRUS statistical
report: Primary brain and other central nervous system tumors
diagnosed in the United States in 2009–2013. Neuro Oncol. 18 (Suppl
5):v1–v75. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Lee G, Auffinger B, Guo D, Hasan T,
Deheeger M, Tobias AL, Kim JY, Atashi F, Zhang L, Lesniak MS, et
al: Dedifferentiation of glioma cells to glioma stem-like cells by
therapeutic Stress-induced HIF signaling in the recurrent GBM
model. Mol Cancer Ther. 15:3064–3076. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Young TL, Matsuda T and Cepko CL: The
noncoding RNA taurine upregulated gene 1 is required for
differentiation of the murine retina. Curr Biol. 15:501–512. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Long J, Menggen Q, Wuren Q, Shi Q and Pi
X: Long noncoding RNA taurine-upregulated gene1 (TUG1) promotes
tumor growth and metastasis through
TUG1/Mir-129-5p/astrocyte-elevated gene-1 (AEG-1) axis in malignant
melanoma. Med Sci Monit. 24:1547–1559. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Liao Y, Zhang B, Zhang T, Zhang Y and Wang
F: LncRNA GATA6-AS promotes cancer cell proliferation and inhibits
apoptosis in glioma by downregulating lncRNA TUG1. Cancer Biother
Radiopharm. 34:660–665. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Katsushima K, Natsume A, Ohka F, Shinjo K,
Hatanaka A, Ichimura N, Sato S, Takahashi S, Kimura H, Totoki Y, et
al: Targeting the Notch-regulated non-coding RNA TUG1 for glioma
treatment. Nat Commun. 7:136162016. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Cai H, Liu X, Zheng J, Xue Y, Ma J, Li Z,
Xi Z, Li Z, Bao M and Liu Y: Long non-coding RNA taurine
upregulated 1 enhances tumor-induced angiogenesis through
inhibiting microRNA-299 in human glioblastoma. Oncogene.
36:318–331. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Tang T, Cheng Y, She Q, Jiang Y, Chen Y,
Yang W and Li Y: Long non-coding RNA TUG1 sponges miR-197 to
enhance cisplatin sensitivity in triple negative breast cancer.
Biomed Pharmacother. 107:338–346. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Xie D, Zhang H, Hu X and Shang C:
Knockdown of long non-coding RNA Taurine Up-Regulated 1 inhibited
doxorubicin resistance of bladder urothelial carcinoma via
Wnt/β-catenin pathway. Oncotarget. 8:88689–88696. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Pećina-Šlaus N, Kafka A, Tomas D, Marković
L, Okštajner PK, Sukser V and Krušlin B: Wnt signaling
transcription factors TCF-1 and LEF-1 are upregulated in malignant
astrocytic brain tumors. Histol Histopathol. 29:1557–1564.
2014.
|
|
36
|
Kim KH and Roberts CW: Targeting EZH2 in
cancer. Nat Med. 22:128–134. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
McCabe MT and Creasy CL: EZH2 as a
potential target in cancer therapy. Epigenomics. 6:341–351. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Chase A and Cross NC: Aberrations of EZH2
in cancer. Clin Cancer Res. 17:2613–2618. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Orzan F, Pellegatta S, Poliani PL, Pisati
F, Caldera V, Menghi F, Kapetis D, Marras C, Schiffer D and
Finocchiaro G: Enhancer of Zeste 2 (EZH2) is up-regulated in
malignant gliomas and in glioma stem-like cells. Neuropathol Appl
Neurobiol. 37:381–394. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Xu H, Zhao G, Zhang Y, Jiang H, Wang W,
Zhao D, Hong J, Yu H and Qi L: Mesenchymal stem cell-derived
exosomal microRNA-133b suppresses glioma progression via
Wnt/β-catenin signaling pathway by targeting EZH2. Stem Cell Res
Ther. 10:3812019. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Han B, Meng X, Wu P, Li Z, Li S, Zhang Y,
Zha C, Ye Q, Jiang C, Cai J and Jiang T: ATRX/EZH2 complex
epigenetically regulates FADD/PARP1 axis, contributing to TMZ
resistance in glioma. Theranostics. 10:3351–3365. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Jin X, Kim LJY, Wu Q, Wallace LC, Prager
BC, Sanvoranart T, Gimple RC, Wang X, Mack SC, Miller TE, et al:
Targeting glioma stem cells through combined BMI1 and EZH2
inhibition. Nat Med. 23:1352–1361. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Kim E, Kim M, Woo DH, Shin Y, Shin J,
Chang N, Oh YT, Kim H, Rheey J, Nakano I, et al: Phosphorylation of
EZH2 activates STAT3 signaling via STAT3 methylation and promotes
tumorigenicity of glioblastoma stem-like cells. Cancer Cell.
23:839–852. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Suvà ML, Riggi N, Janiszewska M,
Radovanovic I, Provero P, Stehle JC, Baumer K, Le Bitoux MA, Marino
D, Cironi L, et al: EZH2 is essential for glioblastoma cancer stem
cell maintenance. Cancer Res. 69:9211–9218. 2009. View Article : Google Scholar
|
|
45
|
Khani P, Nasri F, Khani Chamani F, Saeidi
F, Sadri Nahand J, Tabibkhooei A and Mirzaei H: Genetic and
epigenetic contribution to astrocytic gliomas pathogenesis. J
Neurochem. 148:188–203. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Mazor T, Pankov A, Johnson BE, Hong C,
Hamilton EG, Bell RJA, Smirnov IV, Reis GF, Phillips JJ, Barnes MJ,
et al: DNA methylation and somatic mutations converge on the cell
cycle and define similar evolutionary histories in brain tumors.
Cancer Cell. 28:307–317. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Eich ML, Athar M, Ferguson JE III and
Varambally S: EZH2-targeted therapies in cancer: Hype or a reality.
Cancer Res. 80:5449–5458. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Brennan CW, Verhaak RG, McKenna A, Campos
B, Noushmehr H, Salama SR, Zheng S, Chakravarty D, Sanborn JZ,
Berman SH, et al: The somatic genomic landscape of glioblastoma.
Cell. 155:462–477. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Bian EB, Li J, Xie YS, Zong G, Li J and
Zhao B: LncRNAs: New players in gliomas, with special emphasis on
the interaction of lncRNAs With EZH2. J Cell Physiol. 230:496–503.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Bian EB, Li J, He XJ, Zong G, Jiang T, Li
J and Zhao B: Epigenetic modification in gliomas: Role of the
histone methyltransferase EZH2. Expert Opin Ther Targets.
18:1197–1206. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Viré E, Brenner C, Deplus R, Blanchon L,
Fraga M, Didelot C, Morey L, Van Eynde A, Bernard D, Vanderwinden
JM, et al: The polycomb group protein EZH2 directly controls DNA
methylation. Nature. 439:871–874. 2006. View Article : Google Scholar
|
|
52
|
Ning X, Shi Z, Liu X, Zhang A, Han L,
Jiang K, Kang C and Zhang Q: DNMT1 and EZH2 mediated methylation
silences the microRNA-200b/a/429 gene and promotes tumor
progression. Cancer Lett. 359:198–205. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Wang R and Liu X: Epigenetic regulation of
prostate cancer. Genes Dis. 7:606–613. 2019. View Article : Google Scholar : PubMed/NCBI
|
